Europe’s entrepreneurs are pushing. When will the capital markets pull?
THE SO WHAT
Operator reality in Europe is now a timing problem, not a talent problem — founders are building into AI, climate, and deeptech while public markets and late-stage capital remain structurally conservative. If you’re scaling in Europe, assume longer private-market dependency and design cap tables, secondary options, and US/ME co-investor routes accordingly.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureSBI Funds IPO Anchor Book 20 Times Subscribed; Draws Capital Group, BlackRock, Goldman, ADIA, GIC
A 20x oversubscribed anchor book from names like Capital Group, BlackRock, Fidelity, ADIA, and GIC is a reminder that global capital is still hungry for scaled, regulated asset managers in growth markets. If you’re building infra or tooling around asset management in India, this is a demand signal for distribution, compliance, and data rails that can support much larger flows.
Startups & VenturePhoebe Gates Startup Draws Tracking Scrutiny
Overwriting affiliate tracking cookies to redirect commissions is exactly the kind of growth hack that now gets litigated in public. Any commerce or adtech product that touches attribution needs a clear, auditable story on whose incentives it’s rewriting—and consent flows to match.
I'm a writer who left LA for an AI startup in San Francisco. It was like stepping into a whole new world.
Non-technical talent jumping coasts for early-stage AI startups is a reminder that narrative, ops, and GTM are now as scarce as model talent. Founders should treat strong generalists from adjacent creative fields as core hires, not nice-to-have marketing add-ons.
Startups & VentureReed Jobs would rather talk about curing cancer than his last name
A 17-person Yosemite team leaning into oncology as blockbuster patents expire means more capital chasing post-patent white space—companion diagnostics, delivery tech, and next-gen therapies. If you operate in healthcare or biotech tooling, expect sharper diligence around real clinical leverage, not just AI-on-biology narratives.